Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

IVD Medical Holding Limited
華檢醫療控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1931)

VOLUNTARY ANNOUNCEMENT

BUSINESS UPDATE

Announces the launch of "IVDNewCo Exchange"

The world's first RWA exchange ecosystem focusing on medical innovative drug NewCo high-tech assets and the "IVDD" stablecoin programme

This announcement is made by IVD Medical Holding Limited (the "**Company**" or "**IVD Medical**", together with its subsidiaries, collectively the "**Group**") on a voluntary basis to provide the latest information on the Group's business development to the shareholders (the "**Shareholders**") and potential investors of the Company.

The board (the "**Board**") of directors ("**Directors**") of the Company is pleased to announce that the Company is actively pursuing a landmark strategic initiative to build a "NewCo + RWA" Web3 exchange ecosystem (the "**Ecosystem**") centred on high-tech assets of innovative medical drugs. The Ecosystem will be named "IVDNewCo Exchange" (the "**Exchange**"), and will be accompanied by the issuance of a proprietary stablecoin, IVDDollar ("**IVDD**").

This strategy aims to disrupt the traditional pharmaceutical industry development rules by integrating Web3 technologies (including RWA real-world asset tokenization, blockchain transactions, and stablecoin mechanisms) to enhance the liquidity, financing efficiency, and accessibility of global medical innovative drug assets. The strategic vision, progress, inherent advantages, and future plans of this ecosystem will be elaborated below.

I. STRATEGIC VISION: BUILDING A WEB3 EXCHANGE ECOSYSTEM BASED ON THE ASSETS OF MEDICAL INNOVATIVE DRUG NEWCO

"NewCo + RWA" Web3 exchange ecosystem of IVD Medical is positioned as a leading global decentralised Web3 trading platform based on high-tech medical innovative drug assets ("**NewCo**"). The core of this ecosystem lies in the deep integration of the Company's globally acquired pipeline assets of potential innovative drugs (i.e., NewCo assets) or high-tech assets with potential value in the field with Web3 technology, forming a closed-loop system of "exchange + stablecoin" to address the pain points long faced by the innovative drug industry, such as low financing efficiency, poor asset liquidity, and high globalisation thresholds.

1. Ecological Foundation: Integration of NewCo Assets and Web3 Technology

- Core Value of NewCo's Assets: The Company is actively acquiring and integrating high-potential innovative drug pipeline assets globally (including North America, Europe, and Asia). These assets represent top-tier intellectual property (IP), covering cutting-edge fields such as gene therapy, targeted drugs, and diagnostic technologies. The NewCo model enhances its value through specialised operations (such as asset incubation, clinical development, and commercialization), while the embedding of Web3 technology further revolutionises its distribution and financing mechanisms.

- Web3 Ecosystem Architecture: This ecosystem is centred on the "IVDNewCo Exchange" platform, embedding three key pillars:

  - Real World Asset (RWA) Tokenization: Tokenizing NewCo's intellectual property and other medical IPs (e.g., patents, pipeline interests) converted into on-chain tokens (RWA) to achieve fractionalized and transparent asset transactions.

  - Decentralised Exchange (DEX): "IVDNewCo Exchange" serves as a trading hub, supporting the buying, selling, auctioning, and derivatives trading of NewCo-RWA tokens, and providing low-friction cross-border settlement services.

  - Stablecoin Mechanism: Issuing a proprietary stablecoin "IVDD", pegged to the US dollar/Hong Kong dollar or other fiat currencies (and/or other eligible virtual currencies), to serve as a universal medium for transactions within the ecosystem. IVDD will be used to pay transaction fees, purchase assets, and for cross-border financing, ensuring price stability and liquidity.

- Efficiency Enhancement and Rule Transformation: Through Web3 technology, this ecosystem will shorten the value realization and circulation cycle of medical innovative drugs from traditional years to within one year or even several months, and enable 24/7 global transactions. For example, investors can directly participate in the early-stage financing of NewCo assets through IVDNewCo Exchange, while the stablecoin IVDD simplifies cross-border capital flows. This

not only accelerates asset turnover but also breaks down geographical restrictions, transforming innovative drug research and development from a "closed" to an "open" ecosystem.

2. Ecological Naming and Positioning

- Tentative Exchange Name: "IVDNewCo Exchange" – Redefining the core of the "IVD" brand: Innovation, Verification, Development, emphasising the combination of the Company's foundation in the "IVD" field and NewCo assets.

- Tentative Stablecoin name: IVDDollar ("IVDD") – serving as the ecosystem's payment and value storage tool, reflecting its strong correlation with NewCo assets.

- Strategic Positioning: This ecosystem is not merely a trading platform, but also the cornerstone of a global innovative drug Web3 ecosystem, aiming to become the "Nasdaq + Uniswap" style benchmark in the field of medical RWA.

II. BUSINESS PROGRESS: INTERNATIONAL LICENCE LAYOUT AND COMPLIANCE PROCESS

To support the global operation of the Ecosystem, the Company has initiated multiple cross-border compliance efforts, highlighting its internationalisation strategy:

- Hong Kong Stablecoin Licence Application: The Company is actively preparing for the stablecoin licence application, leveraging Hong Kong's policy advantages as a global financial hub and virtual asset centre. The relevant application is expected to be submitted to the Hong Kong Monetary Authority.

- US Stablecoin Licence Application: Based on the Company's initiated plan for a proposed dual primary listing in the United States by way of a proposed initial public offering of its American depositary shares on the Nasdaq Stock Market in the United States, the Group has simultaneously commenced preparations for applying for a stablecoin licence in the United States. This includes communication with agencies such as the SEC and CFTC, ensuring IVDD complies with the US regulatory framework. In the future, US listings will form a "coin-stock linkage" with the Web3 ecosystem, meaning stablecoin holders may enjoy equity-related rights (such as preferential subscription rights) to promote capital synergy.

- Future Licence Acquisition Plan: The Company plans to successively acquire other necessary compliance licences, such as virtual asset service provider (VASP) licences, and relevant permits in the European Union, Singapore, and other regions, to build a global compliance network.

III. ENDOWED ADVANTAGES: IVD MEDICAL'S COMPETITIVE BARRIERS AND SYNERGY WITH NEW BUSINESSES

This new business direction deeply integrates IVD Medical's core strengths in pharmaceutical distribution networks, commercialization capabilities, and global presence, ensuring the feasibility of ecological implementation:

- Extensive distribution and customer network: As of the end of 2024, the Group had established a robust pharmaceutical commercialization network, comprising 351 direct customers (covering hospitals and medical institutions) and 1,253 distributors. More importantly, through our sub-distribution networks, we cover 1,674 Class III hospitals in China (accounting for approximately 70% of the total Class III hospitals in China), which not only provides a ready-made commercialization channel for NewCo assets and introduces real users and data flows into the Web3 ecosystem. For example, hospital clients can directly trade NewCo-RWA tokens on the IVDNewCo Exchange, accelerating the market penetration of innovative drugs.

- BD Network Competitive Advantage: The Group's Business Development (BD) network has accumulated deep industry relationships and data insights, enabling us to "precisely screen" global NewCo asset acquisitions and quickly identify high-value IP assets. At the same time, the network provides underlying trust for the Web3 ecosystem, attracting institutional investors to participate.

- High-tech Genes: As a pioneer in the field of intellectual property capitalization for innovative drugs, the Company focuses on the management of top-tier intellectual property. The IP library (such as the patent portfolio) of NewCo's assets will become the core underlying asset for RWA tokenization, ensuring the Ecosystem's asset quality and technological barriers.

IV. (SPECIAL SUPPLEMENTARY NOTE) STRATEGIC DEEPENING VISION — GRAND BLUEPRINT OF IVD MEDICAL IVDNEWCO CHAIN ECOSYSTEM

Adhering to the development philosophy of "innovation-driven and technology-led," the Company remains committed to enhancing the efficiency and global competitiveness of the pharmaceutical value chain. Based on a deep insight into the development trends of the global innovative drug industry, the Company keenly recognises that traditional financing mechanisms have many limitations in supporting the efficient development and commercialization of innovative drug pipeline assets, including insufficient asset liquidity, lengthy financing cycles, and challenges such as cross-border collaboration barriers.

To disrupt this established landscape, the Company is actively leading a revolutionary transformation that integrates high-tech intellectual property with Web3 digital technology. It is committed to building a new ecosystem for IVDNewCo Chain, which is based on high-tech assets for innovative medical drugs ("NewCo" assets) and embedded with a Web3 technology framework. This will create a comprehensive platform integrating a Real World Assets (RWA) exchange, a stablecoin system, and global

financial infrastructure. Through this, IVD Medical will chart a future growth path with highly differentiated competitiveness.

In the traditional model, new drug research and development has a long cycle, limited financing, and high globalisation barriers. The highly disruptive "IVDNewCo Chain" ecosystem we envision is not merely an extension of IVDNewCo Exchange, but a complete Web3 ecosystem centred on the intellectual property of innovative drug NewCo. The vision of this ecosystem is to transform NewCo assets into globally liquid RWAs through blockchain technology, building a "token-equity linkage" closed loop, and ultimately achieving a paradigm shift in efficiency for the innovative drug industry.

1. Ecosystem Core: NewCo-RWA as the Value Cornerstone

- We focus on the intellectual property of innovative drug NewCo (such as pipeline interests, patents, and data assets), tokenizing them into on-chain RWA. These RWAs represent real, high-growth medical IP and are traded on the "IVDNewCo Exchange". The uniqueness of the ecosystem lies in its customization for the medical industry. For example, RWA tokens can be embedded in smart contracts to automatically distribute R&D milestone benefits (e.g., dividends upon successful clinical trials).

- Scalability: In addition to the NewCo assets, the ecosystem will gradually incorporate other high-value IPs (such as diagnostic technologies and health data). Tokenized shares of listed companies in the global biomedical sector can also be traded on the IVDNewCo Exchange, helping the ecosystem form a diversified RWA asset pool and enhance its risk resistance capabilities.

2. Web3 Technology Architecture: Exchanges, Stablecoins and Decentralised Autonomous

- Exchange Layer: "IVDNewCo Exchange" adopts a hybrid architecture (combining centralised efficiency with decentralised security) and supports cross-chain transactions (such as Ethereum, Solana) to achieve seamless global circulation of NewCo-RWA. Features include:

  – Auction-style financing: Start-up pharmaceutical companies can initiate tokenized financing through exchanges, with global investors bidding in IVDD.

  and.

  – Derivatives Market: Launch futures and options based on NewCo-RWA to meet hedging needs.

- Stablecoin Layer: "IVDD" serves as the ecosystem's lifeblood, not only for transactions but also for integration into DeFi protocols (such as lending and staking). For example, users can stake IVDD to earn NewCo asset yields. Its stability is guaranteed by reserves (partially pegged to the Company's US dollar assets) and an algorithmic mechanism.

- Autonomous Expansion: The ecosystem will introduce DAO (Decentralised Autonomous Organisation) governance, allowing token holders to vote on the acquisition direction of NewCo assets, ensuring community-driven development.

3. **Efficiency Acceleration Mechanism: Globalisation, Liquidity and Economies of Scale**

   - Asset Liquidity Revolution: Web3 technology removes geographical and time limitations. For example, a European biotech company can tokenize NewCo assets through the exchange, attracting Asian capital within hours and increasing financing efficiency by more than 5 times.

   - Expanded Financing Scale: The ecosystem will aggregate retail and institutional investors (such as hedge funds, pharmaceutical companies), expanding traditional multi-million dollar financing to a global multi-billion dollar market through tokenization.

   - Globalised Network: With Hong Kong as its Asian hub and the United States as its Americas base, the ecosystem will establish multi-regional nodes (such as Singapore and Switzerland) to cover major regulatory zones worldwide, forming a "24/7 trading loop."

4. **Token-Equity Linkage: Strategic Synergy and Value Capture**

   - As a listed company, we regard "token-stock linkage" as our core ecological strategy: IVDD holders can enjoy linkage benefits with IVD Medical Holding Limited shares (01931.HK and future US-listed shares). This move not only attracts Web3 native users but also introduces traditional stock market capital into the ecosystem, forming a "virtual-real" capital cycle and amplifying the Company's market capitalization.

Strategic Significance: The IVDNewCo Chain ecosystem is not merely a technological application, but a reconstruction of the value chain in the medical innovative drug industry. It addresses industry pain points through Web3 — significantly reducing financing costs, accelerating new drug launch cycles, and optimising global resource allocation. The Board firmly believes that the "NewCo + RWA" Web3 Exchange Ecosystem operating model will completely rewrite the capital efficiency and globalization process of the medical innovative drug industry. By combining top-tier IP resources, a global compliant network, and Web3 technology, IVD Medical is expected to forge a new development path, creating long-term value for shareholders and global investors.

The Company has been actively exploring new opportunities and possibilities with an aim to promote return to its shareholders. Announcement(s) will be made on the Group's development in compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (where applicable) as and when appropriate.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
IVD Medical Holding Limited
Lin Xianya
Executive Director

Hong Kong, 17 July 2025

As at the date of this announcement, the Board comprises three executive directors, namely, Mr. Lin Xianya, Mr. Chan Siu Kei Ken and Mr. Law Kim Fai, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and six independent non-executive directors, namely, Dr. Zhong Renqian, Dr. Leung Ka Sing, Dr. Wong Sze Lok, Ms. Tai Yang, Mr. Xu Da and Mr. Zhang Jianlei.

This announcement contains forward-looking statements that reflect the Company's beliefs, plans or expectations about the future or future events. These statements are based on a number of assumptions, current estimates and projections, and are subject to risks, uncertainties and factors which may be beyond control. Actual outcomes may differ. These statements is not, and shall not be, relied upon as any assurance or representation as to the future or as a representation or warranty otherwise. Neither the Company nor its directors, officers, employees, agents, affiliates, advisers or representatives assume any responsibility to update these statements or to adapt them to future events or developments or to provide supplemental information in relation thereto or to correct any inaccuracies.

If there is any inconsistency between the Chinese and English versions of this announcement, the Chinese version shall prevail.